Single nucleotide and copy number variants associated with Parkinson disease

与帕金森病相关的单核苷酸和拷贝数变异

• 批准号: 10409630
• 负责人: JAMES ASHE
• 金额: --
• 依托单位: MINNEAPOLIS VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2022-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10409630
• 关键词: Address; Affect; African American; Area; Biological; Biological Markers; Biology; Blood Tests; Cholesterol; Clinic; Clinical; Clinical Trials; Collection; Communities; Computer software; Copy Number Polymorphism; Craniocerebral Trauma; DNA; DNA copy number; Data; Data Set; Disease; Disease Progression; Environment; Environmental Risk Factor; European; Exposure to; Future; Gene Expression; General Population; Genes; Genetic; Genetic Risk; Genome; Genotype; Goals; Hematological Disease; Heritability; Hispanic Americans; Hispanics; Individual; Intake; Intervention Trial; Java; Learning; Lipids; Measures; Mediating; Mendelian randomization; Meta-Analysis; Mitochondria; Mitochondrial DNA; Molecular; Morbidity - disease rate; Mutation; Natural Selections; Neurodegenerative Disorders; Noise; Nuclear; Nucleic Acid Regulatory Sequences; Nucleotides; Parkinson Disease; Participant; Pathology; Patient Care; Patients; Pesticides; Pharmaceutical Preparations; Population; Population Study; Quantitative Trait Loci; Questionnaires; Research Personnel; Resources; Rest; Risk; Running; Sample Size; Secondary to; Series; Signal Transduction; Single Nucleotide Polymorphism; Susceptibility Gene; Test Result; Testing; Transcript; Traumatic Brain Injury; United States Department of Veterans Affairs; Variant; Veterans; base; clinical care; disorder risk; drug development; experimental study; gene environment interaction; gene interaction; genetic linkage analysis; genetic risk factor; genetic testing; genetic variant; genome wide association study; genome-wide; improved; instrument; interest; mRNA Expression; mitochondrial dysfunction; mortality; new therapeutic target; novel; novel strategies; pesticide exposure; programs; randomized trial; response; risk stratification; risk variant; therapeutic target; trait

The Million Veteran Program (MVP) data set will be used to identify new genetic risk variants— including copy number variants (CNVs: deletions and duplications in the genome)—for Parkinson disease (PD). Previously identified genetic risk factors will be better characterized by testing all pairwise gene-by-gene interactions and testing if variants associated with mRNA expression levels are predictive of PD risk using PrediXcan. The MVP intake questionnaire captured previously identified environmental risk factors such as head trauma (traumatic brain injury) and pesticide exposure; these will be accounted for in the study through gene-by- environment tests to determine if the effects of variants are mediated by these exposures. This will also be the first GWAS of PD to analyse significant Hispanic and African American populations, which will reveal if the variants identified using individuals of European descent are generalizable to other populations. In addition, replication of an association between lower mitochondrial DNA copy number (mtDNA CN) in the blood and PD will be attempted, possibly establishing mtDNA CN as a biomarker for PD risk and progression, which could later be used in clinical trials or even in the clinic. mtDNA CN will be measured using a novel approach that we developed to determine the relative signal intensity for mitochondrial probes on a GWAS array compared to the corresponding signal intensity for nuclear probes. Mendelian randomization experiments would then be employed to see if there is evidence that low mtDNA CN causes PD or whether the PD pathology causes the mtDNA CN to decrease. These experiments will reveal new information regarding the biology of Parkinson disease, allow for better risk stratification, and potentially reveal targets for novel therapeutics.

百万退伍军人计划（MVP）数据集将用于识别新的遗传风险变体 - 包括副本编号变体（CNV：基因组中的删除和重复） - 帕金森病（PD）。先前确定的遗传危险因素将更好地表征 测试所有成对基因的基因相互作用和测试是否与mRNA相关 表达水平可以预测使用Predixcan的PD风险。 MVP进气问卷 捕获了先前确定的环境风险因素，例如头部创伤（创伤性大脑） 受伤）和农药暴露；这些将在研究中通过基因来解释 环境测试以确定变体的影响是否由这些暴露介导。这 也将是PD的第一个分析重要的西班牙裔和非裔美国人的GWA 种群，这将揭示是否使用欧洲血统个体确定的变体是 可以推广到其他人群。此外，复制较低之间的关联 将尝试使用血液和PD中的线粒体DNA拷贝数（mtDNA CN），可能 建立mtDNA CN作为PD风险和进展的生物标志物，以后可以使用 在临床试验甚至在诊所中。 mtDNA CN将使用一种新方法来测量 我们开发以确定GWAS上线粒体问题的相对信号强度 与核问题的相应信号强度相比，阵列。门德利安 然后，随机化实验将是员工，以查看是否有较低mtDNA的证据 CN导致PD或PD病理学是否导致mtDNA CN减少。这些 实验将揭示有关帕金森氏病生物学的新信息，允许 更好的风险分层，并有可能揭示新治疗的靶标。